Standard BioTools Inc. and its directors allegedly misled investors about a proposed merger with SomaLogic Inc., filing a prospectus that omitted or misrepresented key details about the transaction, according to a complaint filed Tuesday.
The biotechnology company’s proposed deal to combine with SomaLogic was pitched to Standard BioTools shareholders on Dec. 1 in a proxy that was lacking financial projections for the combined company, analyses that supported financial advisor Centerview Partners LLC’s fairness opinion, and other background of the transaction, according to the complaint filed in US District Court for the District of Delaware.
The transaction, which directors ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.